en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Guide › Research And Regulatory Status — Beginner to Advanced

Research And Regulatory Status — Beginner to Advanced

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-15 · Guide

If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Handling, Analysis, and Quality Control

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Background and Molecular Identity

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

Related pages on this site

Mechanism and Regulatory Status

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Notes from published material

=== Physical properties === Cadmium is a soft, malleable, ductile, silvery-white divalent metal. It is similar in many respects to zinc but forms complex compounds. Unlike most other metals, cadmium is resistant to corrosion and is used as a protective plate on other metals. As a bulk metal, cadmium is insoluble in water and is not flammable; however, in its powdered form it may burn and release toxic fumes.

A systemic allergic response can cause life-threatening anaphylaxis. In anaphylaxis (a severe systemic reaction to allergens, such as nuts, bee stings, or drugs), the body-wide degranulation of mast cells leads to vasodilation and, if severe, symptoms of life-threatening shock. Products released from these granules include histamine, serotonin, heparin, chondroitin sulphate, tryptase, chymase, carboxypeptidase, and TNF-α. These can vary in their quantities and proportions between individuals, which may explain some of the differences in symptoms seen across patients. Anaphylaxis and MCAS are interrelated but distinct conditions.

=== Rating scale === Several rating instruments have been developed, but their utility in clinical practice remains debated. The most commonly used scale is the Bush-Francis Catatonia Rating Scale (BFCRS). The scale consists of 23 items. The first 14 serve as a screening tool; if 2 of the 14 are positive, this prompts for further evaluation and completion of the remaining 9 items. Diagnostic certainty may also be supported by:

In Konsumentombudsmannen v Gourmet AB the Court suggested that a total ban for advertising alcohol on the radio, TV and in magazines could fall within article 34 where advertising was the only way for sellers to overcome consumers' "traditional social practices and to local habits and customs" to buy their products, but again the national courts would decide whether it was justified under article 36 to protect public health. Under the Unfair Commercial Practices Directive, the EU harmonised restrictions on restrictions on marketing and advertising, to forbid conduct that distorts average consumer behaviour, is misleading or aggressive, and sets out a list of examples that count as unfair. Increasingly, states have to give mutual recognition to each other's standards of regulation, while the EU has attempted to harmonise minimum ideals of best practice. The attempt to raise standards is hoped to avoid a regulatory "race to the bottom", while allowing consumers access to goods from around the continent.

== Major leagues == Epstein was first brought up for six games by the Baltimore Orioles in 1966, at the age of 23. After the Orioles tried in vain to convert him to the outfield (they already had Boog Powell at first base), they demoted him to Rochester again. The outspoken Epstein refused to report, going home to California and continuing his schooling instead. He was traded along with Frank Bertaina from the Orioles to the Washington Senators for Pete Richert on 29 May 1967, going from one of the best organizations in baseball to one of the worst. Later that season, in his first at-bat against the Orioles, Epstein hit a grand slam. In 1968 he was fourth in the league in getting hit by pitches HBP (9). In 1969 with the Senators, in only 403 at bats Epstein hit 30 home runs (ninth in the American League), had 85 runs batted in (RBIs), and hit for a .278 batting average (and .347 with runners in scoring position) with an excellent .414 on-base percentage and .551 slugging percentage. He was fourth in the league in hit by pitch (10), and he hit a home run every 13.4 at bats. He was 25th in voting for the American League MVP. This was also the only year in which the reconstituted Senators (now the Texas Rangers) finished above .500. In 1970, he was second in the league in being hit by a pitch (13), while hitting 20 home runs, and leading all AL first basemen in range factor (10.08). In 1969-70, he was managed by Hall of Fame hitting great Ted Williams.

Sources: en.wikipedia.org

Further detail

== Function == The endogenous system of opioid receptors is well known for its analgesic potential; however, the exact role of δ-opioid receptor activation in pain modulation is largely up for debate. This also depends on the model at hand since receptor activity is known to change from species to species. Activation of delta receptors produces analgesia, perhaps as significant potentiators of μ-opioid receptor agonists. However, it seems like delta agonism provides heavy potentiation to any mu agonism. Therefore, even selective mu agonists can cause analgesia under the right conditions, whereas under others can cause none whatsoever. It is also suggested however that the pain modulated by the μ-opioid receptor and that modulated by the δ-opioid receptor are distinct types, with the assertion that DOR modulates the nociception of chronic pain, while MOR modulates acute pain. Evidence for whether delta agonists produce respiratory depression is mixed; high doses of the delta agonist peptide DPDPE produced respiratory depression in sheep. In contrast both the peptide delta agonist Deltorphin II and the non-peptide delta agonist (+)-BW373U86 actually stimulated respiratory function and blocked the respiratory depressant effect of the potent μ-opioid agonist alfentanil, without affecting pain relief.

== Historical note == An. gambiae invaded northeastern Brazil in 1930, which led to a malaria epidemic in 1938/1939. The Brazilian government assisted by the Rockefeller Foundation in a programme spearheaded by Fred Soper eradicated these mosquitoes from this area. This effort was modeled on the earlier success in eradication of Aedes aegypti as part of the yellow fever control program. The exact species involved in this epidemic has been identified as An. arabiensis.

From 1799 to 1812, Legendre served as mathematics examiner for graduating artillery students at the École Militaire and from 1799 to 1815 he served as permanent mathematics examiner for the École Polytechnique. In 1824, Legendre's pension from the École Militaire was stopped because he refused to vote for the government candidate at the Institut National. In 1831, he was made an officer of the Légion d'Honneur. Legendre died in Paris on 9 January 1833, after a long and painful illness, and Legendre's widow carefully preserved his belongings to memorialize him. Upon her death in 1856, she was buried next to her husband in the village of Auteuil, where the couple had lived, and left their last country house to the village. Legendre's name is one of the 72 names inscribed on the Eiffel Tower.

=== Acid fuchsin === Acid fuchsine may be used to stain collagen, smooth muscle, or mitochondria. Acid fuchsin is used as the nuclear and cytoplasmic stain in Mallory's trichrome method. Acid fuchsin stains cytoplasm in some variants of Masson's trichrome. In Van Gieson's picro-fuchsine, acid fuchsin imparts its red colour to collagen fibres. Acid fuchsin is also a traditional stain for mitochondria (Altmann's method).

Sources: en.wikipedia.org

Background from the literature

==== Prohibition on federal employee strikes ==== Section 305 of the Act prohibited federal employees from striking. This prohibition was subsequently repealed and replaced by a similar provision, 5 U.S.C. § 7311, which bars any person who "participates in a strike, or asserts the right to strike against the Government of the United States" from federal employment.

=== Hybridization === In northern Spain C. brunneus and C. jacobsi form a hybrid zone. It has been suggested that the two species diverged during Pleistocene ice age. Both have the same number of chromosomes (2n=17) with three pairs of long metacentric, four pairs of medium acrocentric, and one pair of short acrocentric chromosomes. Using in situ hybridization an extra rDNA sequence is consistently found on the X chromosome in C. brunneus that is absent in C. jacobsi. The additional rDNA is not expressed in either C. brunneus or the hybrids that possess the rDNA sequence. C. brunneus and C. jacobsi can also be differentiated based on song and by the difference in number of stridulatory pegs located on the hind femur. Using a mark and recapture procedure, the lifetime dispersal of C. brunneus and C. jacobsi were estimated to be similar to other grasshopper species that form hybrid zones. C. brunneus and C. jacobsi are dominant during different months. C. brunneus are dominant in August while C. jacobsi are dominant in June and July. Additionally C. brunneus are only found in valley habitats while C. jacobsi are found in both valley and mountain habitats This suggests both seasonal and temporal isolation between the two species. C. brunneus, C. jacobsi, and hybrid females all show a preference for male C. brunneus and C. jacobsi songs over hybrid male songs. Differences in song traits echeme, syllable, and phrase length have a small epistatic effect but cannot be fully explained by genetic factors.

Nylons can also be synthesized from dinitriles using acid catalysis. For example, this method is applicable for preparation of nylon 1,6 from adiponitrile, formaldehyde and water. Additionally, nylons can be synthesized from diols and dinitriles using this method as well.

In addition, legal counsel to the president Harriet Miers and deputy chief of staff to the president Joshua Bolten were both found in contempt of Congress. In 2010, the Justice Department investigator concluded that though political considerations did play a part in as many as four of the attorney firings, the firings were "inappropriately political" but not criminal. According to the prosecutors, there was insufficient evidence to pursue prosecution for any criminal offense.

=== Enzyme production === A significant milestone in the use of K. phaffii in food technology was its GRAS classification by the US Food and Drug Administration, alongside their approval of recombinant proteins. It is now used to produce various enzymes that serve as processing aids and food additives. In bakery production, enzymes produced by genetically modified Komagataella can maintain bread freshness and compensate for variations in flour and malt quality. In brewing, they can reduce beer's alcohol content or modify the flavour and filtration properties of wine. Recombinant expressed phospholipase C is used to degum high-phosphorus vegetable oils by hydrolysing phospholipids. In animal feed, phytase produced by K. phaffii breaks down phytic acid, an antinutrient. Recently, K. phaffii has been used increasingly to produce soy leghemoglobin, a plant heme protein that gives plant-based meat analogues their colour and flavour. This expands the industrial application of K. phaffii from technical enzymes towards functional food ingredients. For this purpose, the yeast utilises its strong methanol-inducible promoters and efficient secretion to produce functional leghemoglobin for use as a food ingredient. Through strain engineering, including optimisation of heme biosynthesis and signal peptides, and controlled fed-batch fermentation, gram-per-litre titres of secreted leghemoglobin have been achieved. This makes large-scale production for meat analogues economically viable.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

Network